The concern of generic rivalry has repeatedly loomed over copyright’s iconic drug, Sildenafil, raising questions about the future of similar medicinal ventures. While early periods saw impressive returns, the exclusivity expiration has created the door for discounted alternatives, likely reducing profitability and creating a genuine danger for sh